NO20061627L - Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer - Google Patents

Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer

Info

Publication number: NO20061627L
Authority: NO; Norway
Prior art keywords: containing compounds; protease inhibitors; cysteine protease; haloalkyl containing; compounds
Prior art date: 2003-09-18

Application number

NO20061627A

Other languages

English (en)

Norwegian (no)

Inventor

John O Link

Sheila Zipfel

Craig J Mossman

Soon H Woo

Original Assignee

Axys Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-18

Filing date

2006-04-10

Publication date

2006-04-10

2006-04-10 Application filed by Axys Pharm Inc filed Critical Axys Pharm Inc

2006-04-10 Publication of NO20061627L publication Critical patent/NO20061627L/no

Links

150000001875 compounds Chemical class 0.000 title abstract 3
239000002852 cysteine proteinase inhibitor Substances 0.000 title 1
125000001188 haloalkyl group Chemical group 0.000 title 1
102000005600 Cathepsins Human genes 0.000 abstract 1
108010084457 Cathepsins Proteins 0.000 abstract 1
102000005927 Cysteine Proteases Human genes 0.000 abstract 1
108010005843 Cysteine Proteases Proteins 0.000 abstract 1
102000035195 Peptidases Human genes 0.000 abstract 1
108091005804 Peptidases Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pulmonology (AREA)
Immunology (AREA)
Neurology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20061627A 2003-09-18 2006-04-10 Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer NO20061627L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US50468003P	2003-09-18	2003-09-18
US56106204P	2004-04-09	2004-04-09
PCT/US2004/030442 WO2005028429A2 (en)	2003-09-18	2004-09-17	Haloalkyl containing compounds as cysteine protease inhibitors

Publications (1)

Publication Number	Publication Date
NO20061627L true NO20061627L (no)	2006-04-10

Family

ID=34381124

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20061627A NO20061627L (no)	2003-09-18	2006-04-10	Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer

Country Status (19)

Country	Link
US (1)	US7547701B2 (pt)
EP (1)	EP1663958B1 (pt)
JP (1)	JP4991295B2 (pt)
KR (1)	KR20060079143A (pt)
AU (1)	AU2004274471A1 (pt)
BR (1)	BRPI0410979A (pt)
CA (1)	CA2521811A1 (pt)
DK (1)	DK1663958T3 (pt)
EA (1)	EA011855B1 (pt)
ES (1)	ES2534222T3 (pt)
LV (1)	LV13440B (pt)
MX (1)	MXPA05012129A (pt)
NO (1)	NO20061627L (pt)
NZ (1)	NZ542865A (pt)
PT (1)	PT1663958E (pt)
RU (1)	RU2007114127A (pt)
SG (1)	SG146658A1 (pt)
TW (1)	TW200524851A (pt)
WO (1)	WO2005028429A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN100430052C (zh) *	2002-03-05	2008-11-05	默克弗罗斯特加拿大有限公司	组织蛋白酶半胱氨酸蛋白酶抑制剂
PT1663958E (pt)	2003-09-18	2015-06-01	Virobay Inc	Compostos contendo haloalquilo como inibidores de protease de cisteína
WO2005058348A1 (en) *	2003-12-11	2005-06-30	Axys Pharmaceuticals, Inc.	Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
US20070105892A1 (en) *	2003-12-23	2007-05-10	Axys Pharmaceuticals, Inc.	Amidino compounds as cysteine protease inhibitors
CA2554626A1 (en) *	2004-01-30	2005-08-18	Schering Aktiengesellschaft	Silinane compounds as cysteine protease inhibitors
CA2580219A1 (en) *	2004-09-17	2006-03-30	Schering Aktiengesellschaft	Polymorphs of the cysteine protease inhibitor n-(1-cyanocyclopropyl)-3-cyclopropylmethanesulfonyl-2(r)-(2,2,2-trifluoro-1(s)-(4-fluorophenyl) ethylamino)propionamide
AR055283A1 (es) *	2004-11-23	2007-08-15	Merck Frosst Canada Ltd	Inhibidores de cisteinproteasa de catepsina
WO2006060494A1 (en) *	2004-12-01	2006-06-08	Schering Aktiengesellschaft	Haloalkyl containing compounds as cysteine protease inhibitors
EP1819667B1 (en) *	2004-12-02	2012-10-17	ViroBay, Inc.	Sulfonamide compounds as cysteine protease inhibitors
US7488848B2 (en)	2005-03-21	2009-02-10	Virobay, Inc.	Alpha ketoamide compounds as cysteine protease inhibitors
US7893093B2 (en) *	2005-03-22	2011-02-22	Virobay, Inc.	Sulfonyl containing compounds as cysteine protease inhibitors
JP2008545720A (ja)	2005-06-02	2008-12-18	メルクフロストカナダリミテツド	カテプシン阻害剤としてのフルオロアルキルアミン誘導体
GB0611654D0 (en) *	2006-06-13	2006-07-19	Medivir Ab	Compounds
WO2008028301A1 (en) *	2006-09-08	2008-03-13	Merck Frosst Canada Ltd.	Prodrugs of inhibitors of cathepsin s
US20100048717A1 (en)	2006-09-25	2010-02-25	MERCK FROSST CANADA LTD, Merk & Co., Inc.	Cathepsin b inhibitors
US7893112B2 (en) *	2006-10-04	2011-02-22	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
EP2079683B1 (en) *	2006-10-04	2015-01-21	Virobay, Inc.	Di-fluoro containing compounds as cysteine protease inhibitors
CA2672494A1 (en)	2006-12-14	2008-06-19	Nps Pharmaceuticals, Inc.	Use of d-serine derivatives for the treatment of anxiety disorders
EP2262370A4 (en) *	2008-04-01	2011-08-31	Virobay Inc	DIFLUOROUS COMPOUNDS AS A CYSTONE PROTEASE INHIBITOR
JP5198220B2 (ja) *	2008-11-13	2013-05-15	東ソ−・エフテック株式会社	アミノ酸誘導体の製造方法
WO2010069069A1 (en) *	2008-12-17	2010-06-24	Merck Frosst Canada Ltd.	Cathepsin b inhibitors
US20120101053A1 (en) *	2009-06-22	2012-04-26	Cameron Black	Cathepsin cysteine protease inhibitors for the treatment of various diseases
US8324417B2 (en) *	2009-08-19	2012-12-04	Virobay, Inc.	Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
EP2681188A4 (en) *	2011-03-02	2015-04-15	Merck Sharp & Dohme	amidation
WO2012119941A1 (en)	2011-03-04	2012-09-13	Prozymex A/S	Peptidyl nitrilcompounds as peptidase inhibitors
CN103502221B (zh)	2011-03-18	2016-03-30	拜耳知识产权有限责任公司	N-(3-氨甲酰基苯基)-1h-吡唑-5-甲酰胺衍生物及其用于防治动物害虫的用途
EP3342765B1 (en)	2015-08-29	2021-09-15	Sunshine Lake Pharma Co., Ltd.	Cathepsin k inhibitor and application thereof
WO2020201572A1 (en)	2019-04-05	2020-10-08	Université De Bretagne Occidentale	Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3599287B2 (ja)	1993-04-28	2004-12-08	三菱化学株式会社	スルホンアミド誘導体
SK6572000A3 (en)	1997-11-05	2000-10-09	Novartis Ag	Dipeptide nitriles, process for the preparation thereof, their use as medicaments and pharmaceutical composition comprising them
EP1159273A1 (en)	1999-03-02	2001-12-05	Boehringer Ingelheim Pharmaceuticals Inc.	Compounds useful as reversible inhibitors of cathepsin s
TW200404789A (en)	1999-03-15	2004-04-01	Axys Pharm Inc	Novel compounds and compositions as protease inhibitors
DE60021254T2 (de)	1999-03-15	2006-04-20	AXYS Pharmaceuticals, Inc., South San Francisco	N-cyanomethylamide als protease inhibitoren
ES2199856T3 (es)	1999-09-13	2004-03-01	Boehringer Ingelheim Pharmaceuticals, Inc.	Nuevos compuestos heterociclicos, utiles como inhibidores reversibles de cisteina proteasas.
US6420364B1 (en) *	1999-09-13	2002-07-16	Boehringer Ingelheim Pharmaceuticals, Inc.	Compound useful as reversible inhibitors of cysteine proteases
EP1212302A1 (en) *	1999-09-16	2002-06-12	Axys Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions as cathepsin s inhibitors
DE60132975T2 (de)	2000-01-06	2009-02-26	Merck Frosst Canada Inc., Kirkland	Neue substanzen und verbindungen als protease-inhibitoren
AU2001245764A1 (en)	2000-03-15	2001-09-24	Axys Pharmaceuticals, Inc.	Novel compounds and compositions as protease inhibitors
CA2439415C (en)	2001-03-02	2011-09-20	Merck Frosst Canada & Co.	Cathepsin cysteine protease inhibitors
SE521652C2 (sv)	2001-03-15	2003-11-25	Canag Diagnostics Ab	En skivepitelcellcancerrelaterad fusionsgen och motsvarande fusionsprotein
EP1397340A2 (en)	2001-06-01	2004-03-17	Axys Pharmaceuticals, Inc.	Chemical compounds and pharmaceutical compositions as cathepsin s inhibitors
CA2459825A1 (en)	2001-10-02	2003-04-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cysteine proteases
CA2463770A1 (en)	2001-10-29	2003-05-08	Boehringer Ingelheim Pharmaceuticals, Inc.	Compounds useful as reversible inhibitors of cysteine proteases
WO2003041649A2 (en) *	2001-11-13	2003-05-22	Merck Frosst Canada & Co.	Cyanoalkylamino derivatives as protease inhibitors
CN100430052C (zh) *	2002-03-05	2008-11-05	默克弗罗斯特加拿大有限公司	组织蛋白酶半胱氨酸蛋白酶抑制剂
US20050288336A1 (en)	2002-05-14	2005-12-29	Axys Pharmaceuticals, Inc.	Cysteine protease inhibitors
US7101880B2 (en)	2002-06-24	2006-09-05	Schering Aktiengesellschaft	Peptidic compounds as cysteine protease inhibitors
US20060166966A1 (en)	2002-10-08	2006-07-27	Cameron Black	4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
US7326719B2 (en)	2003-03-13	2008-02-05	Boehringer Ingelheim Pharmaceuticals, Inc.	Cathepsin S inhibitors
EP1761485A1 (en)	2003-06-04	2007-03-14	Schering AG	Amidino compounds as cysteine protease inhibitors
CA2535366A1 (en)	2003-08-27	2005-03-10	Merck Frosst Canada & Co.	Cathepsin inhibitors
EP1664003A1 (en)	2003-09-18	2006-06-07	Axys Pharmaceuticals, Inc.	Haloalkyl containing compounds as cysteine protease inhibitors
PT1663958E (pt)	2003-09-18	2015-06-01	Virobay Inc	Compostos contendo haloalquilo como inibidores de protease de cisteína
GB0322629D0 (en)	2003-09-26	2003-10-29	Glaxo Group Ltd	Novel compound
WO2005058348A1 (en)	2003-12-11	2005-06-30	Axys Pharmaceuticals, Inc.	Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic
US20070105892A1 (en)	2003-12-23	2007-05-10	Axys Pharmaceuticals, Inc.	Amidino compounds as cysteine protease inhibitors
CA2554626A1 (en)	2004-01-30	2005-08-18	Schering Aktiengesellschaft	Silinane compounds as cysteine protease inhibitors
WO2006034004A2 (en)	2004-09-17	2006-03-30	Schering Aktiengesellschaft	Processes and intermediates for preparing cysteine protease inhibitors
AR055283A1 (es) *	2004-11-23	2007-08-15	Merck Frosst Canada Ltd	Inhibidores de cisteinproteasa de catepsina

2004
- 2004-09-17 PT PT47843321T patent/PT1663958E/pt unknown
- 2004-09-17 TW TW093128291A patent/TW200524851A/zh unknown
- 2004-09-17 EP EP04784332.1A patent/EP1663958B1/en not_active Expired - Lifetime
- 2004-09-17 MX MXPA05012129A patent/MXPA05012129A/es unknown
- 2004-09-17 WO PCT/US2004/030442 patent/WO2005028429A2/en not_active Ceased
- 2004-09-17 NZ NZ542865A patent/NZ542865A/en unknown
- 2004-09-17 EA EA200600588A patent/EA011855B1/ru not_active IP Right Cessation
- 2004-09-17 SG SG200806916-3A patent/SG146658A1/en unknown
- 2004-09-17 AU AU2004274471A patent/AU2004274471A1/en not_active Abandoned
- 2004-09-17 CA CA002521811A patent/CA2521811A1/en not_active Abandoned
- 2004-09-17 DK DK04784332.1T patent/DK1663958T3/da active
- 2004-09-17 US US10/943,768 patent/US7547701B2/en not_active Expired - Lifetime
- 2004-09-17 BR BRPI0410979-1A patent/BRPI0410979A/pt not_active IP Right Cessation
- 2004-09-17 KR KR1020057022300A patent/KR20060079143A/ko not_active Withdrawn
- 2004-09-17 ES ES04784332.1T patent/ES2534222T3/es not_active Expired - Lifetime
- 2004-09-17 JP JP2006527043A patent/JP4991295B2/ja not_active Expired - Fee Related
2005
- 2005-09-16 RU RU2007114127/04A patent/RU2007114127A/ru not_active Application Discontinuation
2006
- 2006-03-23 LV LVP-06-49A patent/LV13440B/lv unknown
- 2006-04-10 NO NO20061627A patent/NO20061627L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
SG146658A1 (en)	2008-10-30
DK1663958T3 (da)	2015-04-07
US7547701B2 (en)	2009-06-16
US20050182096A1 (en)	2005-08-18
RU2007114127A (ru)	2008-10-27
NZ542865A (en)	2009-04-30
PT1663958E (pt)	2015-06-01
BRPI0410979A (pt)	2006-07-04
TW200524851A (en)	2005-08-01
WO2005028429A2 (en)	2005-03-31
WO2005028429A3 (en)	2005-05-19
LV13440B (en)	2006-10-20
MXPA05012129A (es)	2006-02-08
AU2004274471A1 (en)	2005-03-31
ES2534222T3 (es)	2015-04-20
JP2007505920A (ja)	2007-03-15
KR20060079143A (ko)	2006-07-05
EA200600588A1 (ru)	2006-08-25
CA2521811A1 (en)	2005-03-31
EP1663958B1 (en)	2015-02-25
JP4991295B2 (ja)	2012-08-01
EA011855B1 (ru)	2009-06-30
EP1663958A2 (en)	2006-06-07

Legal Events

Date	Code	Title	Description
2010-04-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20061627L (no)	2006-04-10	Haloalkyl inneholdende forbindelser som cysteinproteaseinhibitorer
NO20075370L (no)	2007-12-19	Alfa-ketoamidforbindelser som cysteinproteaseinhibitorer
SE0201980D0 (sv)	2002-06-24	Novel compounds
ATE447574T1 (de)	2009-11-15	3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
SE0201976D0 (sv)	2002-06-24	Novel compounds
IS7817A (is)	2005-04-20	Fenýlalanín afleiður sem dípeptidýl peptíðasa hindrar til að meðhöndla eða fyrirbyggja sykursýki.
EP1651623A4 (en)	2006-10-04	HEXAHYDRODIAZEPINONE AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV FOR TREATMENT OR PREVENTION OF DIABETES
NO20052380L (no)	2005-06-16	Beta-amino-heterosykliske dipeptidylpeptidaseinhibitorer for behandling og forhindring av diabetes
EA200870380A1 (ru)	2009-02-27	Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
ATE451369T1 (de)	2009-12-15	Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
ATE387197T1 (de)	2008-03-15	Cyanoalkylamino-derivate als protease-hemmer
CY1107342T1 (el)	2012-12-19	Χρηση παραγωγων νιτριλιου ως φαρμακο
WO2005063742A3 (en)	2005-08-18	Amidino compounds as cysteine protease inhibitors
MXPA05008240A (es)	2005-10-05	Inhibidores de catepsina s.
NO20063842L (no)	2006-10-20	Silinanforbindelser som cysteinproteaseinhibitorer
AU2003303076A1 (en)	2004-07-09	Cathepsin cysteine protease inhibitors and their use
WO2008042968A3 (en)	2008-05-22	Di-fluoro containing compounds as cysteine protease inhibitors
ATE553090T1 (de)	2012-04-15	Cathepsincysteinproteasehemmer
IL189286A0 (en)	2008-06-05	Novel cysteine protease inhibitors and their therapeutic applications
MX2007011739A (es)	2008-03-14	Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
WO2010056877A3 (en)	2010-07-29	Haloalkyl containing compounds as cysteine protease inhibitors
MX2008007195A (es)	2008-09-10	Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
WO2006034390A3 (en)	2006-06-01	Inhibitors of 15-lipoxygenase
UA95930C2 (uk)	2011-09-26	Інгібітори цистеїнпротеаз, фармацевтична композиція, яка їх містить, та їх терапевтичне застосування
CY1116202T1 (el)	2017-02-08	Ενωσεις που περιεχουν διφθοριο ως αναστολεις των κυστεϊνικων πρωτεασεων